JPWO2020211839A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020211839A5 JPWO2020211839A5 JP2021561927A JP2021561927A JPWO2020211839A5 JP WO2020211839 A5 JPWO2020211839 A5 JP WO2020211839A5 JP 2021561927 A JP2021561927 A JP 2021561927A JP 2021561927 A JP2021561927 A JP 2021561927A JP WO2020211839 A5 JPWO2020211839 A5 JP WO2020211839A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- pharma
- hydroxyl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 amino, methyl Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 4
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 2
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- ASQUQUOEFDHYGP-UHFFFAOYSA-N 2-methoxyethanolate Chemical group COCC[O-] ASQUQUOEFDHYGP-UHFFFAOYSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000005157 alkyl carboxy group Chemical group 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004273 azetidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019083376 | 2019-04-19 | ||
| CNPCT/CN2019/083376 | 2019-04-19 | ||
| PCT/CN2020/085338 WO2020211839A1 (en) | 2019-04-19 | 2020-04-17 | Jak1 selective kinase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529061A JP2022529061A (ja) | 2022-06-16 |
| JPWO2020211839A5 true JPWO2020211839A5 (enExample) | 2024-07-08 |
| JP7555959B2 JP7555959B2 (ja) | 2024-09-25 |
Family
ID=72837031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561927A Active JP7555959B2 (ja) | 2019-04-19 | 2020-04-17 | Ｊａｋ１選択的キナーゼ阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220220096A1 (enExample) |
| EP (1) | EP3956322B1 (enExample) |
| JP (1) | JP7555959B2 (enExample) |
| KR (1) | KR20220003537A (enExample) |
| CN (1) | CN113710664B (enExample) |
| AR (1) | AR118729A1 (enExample) |
| AU (1) | AU2020258619B2 (enExample) |
| BR (1) | BR112021020964A2 (enExample) |
| CA (1) | CA3134174A1 (enExample) |
| DK (1) | DK3956322T3 (enExample) |
| ES (1) | ES3031576T3 (enExample) |
| MX (1) | MX2021012749A (enExample) |
| PT (1) | PT3956322T (enExample) |
| TW (1) | TW202104215A (enExample) |
| WO (1) | WO2020211839A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7613778B2 (ja) * | 2020-11-26 | 2025-01-15 | 科輝智薬（深▲セン▼）新薬研究中心有限公司 | アミド化合物、医薬組成物およびその使用 |
| CN114380806B (zh) * | 2022-03-24 | 2022-06-10 | 中国药科大学 | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 |
| US12240836B2 (en) * | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| EP4554931A1 (en) * | 2022-07-12 | 2025-05-21 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198900B2 (en) * | 2011-11-10 | 2015-12-01 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment of peritoneal injury using JAK inhibitors |
| JP6767491B2 (ja) * | 2015-09-25 | 2020-10-14 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | Ｊａｋを阻害するための化合物及び方法 |
| HRP20230069T1 (hr) * | 2017-01-17 | 2023-03-17 | Astrazeneca Ab | Selektivni inhibitori jak1 |
| WO2020057669A1 (zh) * | 2018-09-21 | 2020-03-26 | 上海轶诺药业有限公司 | 一类具有激酶抑制活性的芳香杂环类化合物 |
-
2020
- 2020-04-17 TW TW109112994A patent/TW202104215A/zh unknown
- 2020-04-17 AR ARP200101101A patent/AR118729A1/es unknown
- 2020-04-17 JP JP2021561927A patent/JP7555959B2/ja active Active
- 2020-04-17 ES ES20790639T patent/ES3031576T3/es active Active
- 2020-04-17 CA CA3134174A patent/CA3134174A1/en active Pending
- 2020-04-17 PT PT207906397T patent/PT3956322T/pt unknown
- 2020-04-17 CN CN202080029899.3A patent/CN113710664B/zh active Active
- 2020-04-17 AU AU2020258619A patent/AU2020258619B2/en active Active
- 2020-04-17 KR KR1020217036576A patent/KR20220003537A/ko not_active Ceased
- 2020-04-17 EP EP20790639.7A patent/EP3956322B1/en active Active
- 2020-04-17 MX MX2021012749A patent/MX2021012749A/es unknown
- 2020-04-17 US US17/604,442 patent/US20220220096A1/en active Pending
- 2020-04-17 DK DK20790639.7T patent/DK3956322T3/da active
- 2020-04-17 BR BR112021020964A patent/BR112021020964A2/pt unknown
- 2020-04-17 WO PCT/CN2020/085338 patent/WO2020211839A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6434416B2 (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| JP4643760B2 (ja) | Ｄｐｐ−ｉｖ阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬 | |
| RU2019120990A (ru) | Бициклические гетероарильные производные в качестве стимуляторов cftr | |
| CA3093851A1 (en) | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same | |
| RU2004117887A (ru) | Ариланилиновые агонисты бета2 адренергических рецепторов | |
| JP2015516434A5 (enExample) | ||
| WO2014145642A9 (en) | Nrf2 small molecule inhibitors for cancer therapy | |
| RU2009123525A (ru) | ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2 | |
| JP2020520957A5 (enExample) | ||
| PT1948176E (pt) | Diaril ureias para tratar a hipertensão pulmonar | |
| JP2025106456A (ja) | 胆管癌を治療するための方法 | |
| JP2005507390A5 (enExample) | ||
| JPWO2020211839A5 (enExample) | ||
| TW201006823A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
| JP2007518798A5 (enExample) | ||
| RU2006126532A (ru) | Бронхорелаксирующие соединения | |
| KR20200123184A (ko) | 증식이상 장애를 치료하기 위한 물질 및 방법 | |
| CN111315750A (zh) | 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物 | |
| US20070004777A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
| US9790225B2 (en) | 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances | |
| RU2021132080A (ru) | Селективный ингибитор киназы JAK1 | |
| RU2646475C2 (ru) | Лечение диабета I и II типа | |
| JPWO2020234782A5 (enExample) | ||
| US8669248B1 (en) | Adenine inhibitors of HSP90 | |
| JP7184302B2 (ja) | ヒトトレフォイル因子３の阻害に有用な化合物 |